News
Imagine treating a genetic disease not by managing symptoms for life, but by correcting the underlying genetic error itself. Inventors at NIH are advancing that vision with a gene editing technology designed to deliver highly precise genetic corrections, opening new possibilities for therapies that
The National Institute of Dental and Craniofacial Research (NIDCR) at the NIH has a great non-exclusive license opportunity available to commercialize a novel adeno-associated virus termed “44-9” (AAV44-9) vector for gene therapy. AAV44-9 based vectors have high gene transfer activity in many cell
Attend the FLC’s Using Valuations in Technology Transfer webinar to hear from NIH Office of Technology Transfer’s (OTT’s) Steve Ferguson on why using valuations is a good start to gathering information needed at various stages of technology transfer. Topics covered include why valuation is needed
Comirnaty®, colloquially known as the Pfizer vaccine, is a messenger RNA (mRNA) vaccine indicated for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This vaccine by BioNTech/Pfizer received full FDA approval on August 23, 2021, after